Biocryst Pharmaceuticals (DE:BO1)
FRANKFURT:BO1
Holding DE:BO1?
Track your performance easily

BioCryst (BO1) Financial Statements

1 Followers

BioCryst Financial Overview

BioCryst's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; BioCryst is scheduled to report earnings on October 30, 2024, and the estimated EPS forecast is €-0.07. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 109.33M$ 92.76M$ 93.40M$ 86.74M$ 82.49M
Gross Profit$ 107.60M$ 91.37M$ 91.76M$ 85.64M$ 81.65M
EBIT$ 12.23M$ -10.51M$ -38.58M$ -8.47M$ -45.67M
EBITDA$ 12.55M$ -10.20M$ -38.16M$ 11.70M$ -24.38M
Net Income Common Stockholders$ -12.67M$ -35.38M$ -61.73M$ -40.26M$ -75.33M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 272.03M$ 336.55M$ 388.99M$ 397.59M$ 412.24M
Total Assets$ 472.42M$ 467.89M$ 516.96M$ 522.92M$ 529.88M
Total Debt$ 327.01M$ 322.33M$ 317.11M$ 310.24M$ 301.51M
Net Debt$ 54.98M$ -14.23M$ -71.87M$ -87.35M$ -110.73M
Total Liabilities$ 948.02M$ 944.06M$ 972.49M$ 933.91M$ 918.60M
Stockholders Equity$ -475.61M$ -476.17M$ -455.53M$ -410.99M$ -388.71M
Cash Flow-
Free Cash Flow$ -1.52M$ -53.92M$ -9.47M$ -20.88M$ -19.28M
Operating Cash Flow$ -1.37M$ -53.68M$ -8.92M$ -19.90M$ -18.81M
Investing Cash Flow$ -2.45M$ 28.76M$ -28.47M$ 23.12M$ -19.04M
Financing Cash Flow$ -1.97M$ -1.05M$ -3.17M$ 1.23M$ 29.36M
Currency in USD

BioCryst Earnings and Revenue History

BioCryst Debt to Assets

BioCryst Cash Flow

BioCryst Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis